Point72 Asset Management L.P. Boosts Stock Position in COMPASS Pathways plc (NASDAQ:CMPS)

Point72 Asset Management L.P. raised its position in shares of COMPASS Pathways plc (NASDAQ:CMPS) by 15.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 67,999 shares of the company’s stock after buying an additional 9,099 shares during the quarter. Point72 Asset Management L.P.’s holdings in COMPASS Pathways were worth $257,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of CMPS. Affinity Asset Advisors LLC raised its stake in shares of COMPASS Pathways by 183.0% during the 4th quarter. Affinity Asset Advisors LLC now owns 850,512 shares of the company’s stock worth $3,215,000 after acquiring an additional 550,000 shares in the last quarter. Barclays PLC grew its holdings in COMPASS Pathways by 2.1% in the fourth quarter. Barclays PLC now owns 419,194 shares of the company’s stock worth $1,585,000 after purchasing an additional 8,718 shares during the last quarter. Renaissance Technologies LLC grew its holdings in COMPASS Pathways by 161.3% in the fourth quarter. Renaissance Technologies LLC now owns 212,700 shares of the company’s stock worth $804,000 after purchasing an additional 131,300 shares during the last quarter. Altium Capital Management LLC purchased a new position in COMPASS Pathways in the fourth quarter worth $5,384,000. Finally, Brown University grew its holdings in COMPASS Pathways by 194.6% in the fourth quarter. Brown University now owns 214,200 shares of the company’s stock worth $810,000 after purchasing an additional 141,500 shares during the last quarter. 46.19% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

CMPS has been the topic of several analyst reports. Cantor Fitzgerald raised shares of COMPASS Pathways to a “strong-buy” rating in a report on Tuesday, May 13th. Canaccord Genuity Group cut their price target on shares of COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, February 28th. Stifel Nicolaus initiated coverage on shares of COMPASS Pathways in a report on Thursday, February 27th. They issued a “buy” rating and a $11.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price target on shares of COMPASS Pathways in a report on Monday, May 12th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $20.20.

COMPASS Pathways Price Performance

Shares of CMPS opened at $4.36 on Friday. The firm has a market capitalization of $404.82 million, a PE ratio of -1.98 and a beta of 2.27. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways plc has a 1-year low of $2.49 and a 1-year high of $8.54. The company’s fifty day moving average price is $3.44 and its 200-day moving average price is $3.93.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.03. On average, equities research analysts predict that COMPASS Pathways plc will post -2.33 EPS for the current year.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.